ArticleJournal of the American Society of Nephrology : JASN2017
Remission of Hematuria Improves Renal Survival in IgA Nephropathy.
Article in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 97 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
97 citing papers in PubMed, 7 syntheses or guidelines pooled it, 157 citations in OpenAlex.
- Evidence-based guidelines for the diagnosis and management of adult-onset IgA vasculitis.Nature reviews. Rheumatology · 2026Guideline
- Efficacy and safety of sibeprenlimab in IgA nephropathy: a systematic review and meta-analysis of randomized controlled trials.BMC nephrology · 2026Pooled it
- Impact of hematuria on long term kidney outcomes in adults with immunoglobulin A nephropathy: a systematic literature review and meta-analysis.Frontiers in nephrology · 2026Pooled it
- Association Between Surrogate Endpoints and Clinical Outcomes in Immunoglobulin A Nephropathy: A Systematic Literature Review.Advances in therapy · 2025Pooled it
- IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2025Guideline
- Lower proteinuria is better for patients with IgA nephropathy: a systematic review.Frontiers in nephrology · 2025Pooled it
- Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis.Renal failure · 2021Pooled it
- Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy.Journal of the American Society of Nephrology : JASN · 2018Trial
- Systematic Review of Persistent Microscopic Hematuria and Kidney Outcomes in IgAN.Kidney international reports · 2026Article
- Chronic kidney disease progression in glomerular diseases: is hematuria a key risk factor?Pediatric nephrology (Berlin, Germany) · 2026Review
- Remission of hematuria is associated with a better prognosis in immunoglobulin A nephropathy.Kidney research and clinical practice · 2026Article
- Hematuria in IgAN: Marker, Mediator, or Both?Kidney international reports · 2026Article
- Persistent Haematuria Is Associated With Reduced Kidney Survival in Primary Podocytopathies.Nephrology (Carlton, Vic.) · 2026Article
- Time-Updated Hematuria and Kidney Disease Progression in IgAN.Kidney international reports · 2026Article
- Measuring effectiveness in immunoglobulin A nephropathy: what are we looking for?Clinical kidney journal · 2026Article
- Review
- Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.Clinical kidney journal · 2026Review
- Principles for Optimal Drug Selection in IgA Nephropathy-Time for Integrating Pathogenesis and Clinical Markers to Guide Therapy.Nephrology (Carlton, Vic.) · 2026Review
- Prognostic relevance of persistent haematuria in patients with lupus nephritis.Clinical kidney journal · 2026Article
- Targeted-release budesonide versus systemic corticosteroids in IgA nephropathy: a real-world comparative study.Frontiers in immunology · 2026Article
37 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hematuria is a cardinal symptom in IgA nephropathy, but its influence on the risk of disease progression has been scarcely investigated. We followed a cohort of 112 patients with IgA nephropathy for a mean±SEM period of 14±10.2 years, during which clinical and analytic risk factors (including urine sediment examination) were regularly recorded. According to the magnitude of time-averaged hematuria, we classified patients as those with persistent hematuria and those with negative or minimal hematuria. We also classified patients according to the magnitude of time-averaged proteinuria (>0.75 or ≤0.75 g/d). The proportion of patients reaching ESRD or a 50% reduction of renal function was significantly greater among patients with persistent hematuria than patients with minimal or negative hematuria (30.4% and 37.0% versus 10.6% and 15.2%, respectively;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.